KRAS and non-small cell lung carcinoma: Kirsten rat sarcoma (KRAS) is the most commonly mutated oncogene in advanced, non-squamous, non-small cell lung cancer (NSCLC), with the G12C mutation being the most prevalent variant (40%), accounting for 10%-13% of advanced non-squamous NSCLC cases.1 Recent breakthroughs transformed the previously undruggable KRAS into a viable therapeutic target.